Ashvattha Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 31

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $30M

  • Investors
  • 37

Ashvattha Therapeutics General Information

Description

Developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases. The company's therapeutics selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body, enabling medical practitioners to treat patients with improved efficacy and reduced side effects.

Contact Information

Website
www.avttx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1235 Radio Road
  • Suite 200
  • Redwood City, CA 94065
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Therapeutic Devices
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1235 Radio Road
  • Suite 200
  • Redwood City, CA 94065
  • United States
+1 (650)

Ashvattha Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ashvattha Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 13-Jan-2025 $30M Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 24-Apr-2023 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series B) 31-May-2020 Completed Startup
5. Early Stage VC (Series A) 31-May-2019 Completed Startup
4. Accelerator/Incubator 01-Mar-2018 Completed Startup
3. Seed Round 01-Jun-2016 Completed Startup
2. Seed Round $900K $900K Completed Startup
1. Grant 01-Jan-2016 $150K Completed Startup
To view Ashvattha Therapeutics’s complete valuation and funding history, request access »

Ashvattha Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Seed-1 412,825 $0.000100 8% $1.45 $1.45 1x $1.45 2.56%
Seed 947,370 $0.000100 8% $0.95 $0.95 1x $0.95 2.56%
To view Ashvattha Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ashvattha Therapeutics Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 12

    Pending

  • Expiring in next 12 mo

Ashvattha Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025226820-A1 Csf1r inhibitor dendrimer conjugates and uses thereof Pending 23-Apr-2024
WO-2025226829-A1 Dendrimer formulations and uses thereof Pending 23-Apr-2024
WO-2025217220-A1 Radiolabeled dendrimer conjugates and methods of use thereof Pending 08-Apr-2024
CA-3222952-A1 Dendrimer conjugates and methods of use thereof Pending 10-Jun-2021
WO-2022261504-A1 Dendrimer conjugates and methods of use thereof Inactive 10-Jun-2021 A61K47/34
To view Ashvattha Therapeutics’s complete patent history, request access »

Ashvattha Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ashvattha Therapeutics Investors (37)

Investor Name Investor Type Holding Investor Since Participating Rounds
A-Level Capital Venture Capital Minority
Angel (individual) Minority
Deep Ventures (Venture Capital) Venture Capital Minority
Evolution VC Partners Venture Capital Minority
Helios Capital (New York) Family Office Minority
You’re viewing 5 of 37 investors. Get the full list »

Ready to get started?

Request a free trial

Ashvattha Therapeutics FAQs

  • When was Ashvattha Therapeutics founded?

    Ashvattha Therapeutics was founded in 2015.

  • Where is Ashvattha Therapeutics headquartered?

    Ashvattha Therapeutics is headquartered in Redwood City, CA.

  • What is the size of Ashvattha Therapeutics?

    Ashvattha Therapeutics has 31 total employees.

  • What industry is Ashvattha Therapeutics in?

    Ashvattha Therapeutics’s primary industry is Drug Discovery.

  • Is Ashvattha Therapeutics a private or public company?

    Ashvattha Therapeutics is a Private company.

  • What is the current valuation of Ashvattha Therapeutics?

    The current valuation of Ashvattha Therapeutics is .

  • What is Ashvattha Therapeutics’s current revenue?

    The current revenue for Ashvattha Therapeutics is .

  • How much funding has Ashvattha Therapeutics raised over time?

    Ashvattha Therapeutics has raised $217M.

  • Who are Ashvattha Therapeutics’s investors?

    A-Level Capital, , Deep Ventures (Venture Capital), Evolution VC Partners, and Helios Capital (New York) are 5 of 37 investors who have invested in Ashvattha Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process